Monalizumab

Preclinical data demonstrate enhanced anti-tumor efficacy by combining PD-1/PD-L1 pathway blockade and NKG2A checkpoint inhibitor; Resistance to PD-1 pathway blockers is associated with upregulation...

Five posters presented by Innate Pharma and collaborators; New data further supporting the rationale of four of Innate’s clinical and preclinical programs; New checkpoint inhibitor program targeting...

Multicenter, open-label, dose-escalation and cohort-expansion Phase I study of durvalumab in combination with monalizumab in patients with solid tumors; Trial performed by AstraZeneca/MedImmune in the...

Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer Trial conducted in Europe and the United States Innate Pharma SA (the...

Third trial opened in the Phase II clinical program of IPH2201 - program rollout on track Trial conducted in the United States with leading investigator at OSU Innate Pharma SA (the “Company” -...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the first patient was treated in the Phase I/II trial testing IPH2201, a first-in-class NKG2A checkpoint...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that the co-development and commercialization agreement with AstraZeneca on Innate Pharma’s proprietary anti-NKG2A antibody...

Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) today announced that it has signed a co-development and commercialization agreement with AstraZeneca, along with MedImmune, its global biologics...

The trial rationale and protocol were presented at the “Targeted Anticancer Therapies” congress in Paris Phase I/II of IPH2201 as a single agent will begin in the next few months Innate Pharma SA (the...

First Phase II of IPH2201, a novel checkpoint inhibitor entering the immuno-oncology field Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...